Neuroendocrine drivers of polyendocrine metabolic ovarian syndrome ( PMOS ) and the modifying role of adiposity
Journal of Neuroendocrinology · 2026-11 · 38 (11)
DOI: 10.1111/jne.70337 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 17.11.2026. Verfasst von Anna Kyriakidou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Endocrinology and Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Hammersmith Hospi…. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Adiposity, Obesity, Neurosecretory Systems. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Medical Research Council.
Abstract (Originalsprache)
Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome (PCOS), is the commonest cause of anovulatory subfertility and represents a substantial and growing healthcare burden. PMOS is a complex neuroendocrine‐ovarian‐metabolic disorder in which dysregulation of the hypothalamic–pituitary–gonadal (HPG) axis disrupts ovarian function, further exacerbated by associated metabolic dysfunction. This review synthesises the current clinical evidence on neuroendocrine dysfunction in PMOS, using luteinising hormone (LH) pulsatility as a surrogate marker of gonadotrophin‐releasing hormone (GnRH) neuronal activity. By drawing on parallel evidence from women with and without PMOS, we examine how adiposity modulates these parameters. In women without PMOS, obesity is associated with hypothalamic suppression. By contrast, a key neuroendocrine feature of PMOS is accelerated hypothalamic pulsatile GnRH neuronal activity, which preferentially drives LH secretion, culminating in ovarian androgen excess, follicular arrest, and anovulation. Although obesity is associated with lower mean LH concentrations due to attenuation of LH pulse amplitude, pulse frequency remains heightened. Given the high prevalence of obesity in PMOS, dampening of raised LH concentrations with obesity challenges its use as part of diagnostic criteria for PMOS in populations where obesity is prevalent. Obesity‐induced metabolic dysfunction also leads to hyperinsulinaemia, which further exacerbates ovarian hyperandrogenism. The interplay between metabolic dysfunction and reproductive health is illustrated by weight‐management interventions, which consistently improve ovulatory function in women with obesity and PMOS. Understanding the neuroendocrine impact of obesity on the pathophysiology of PMOS can inform both diagnostic accuracy and therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Endocrinology and Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Hammersmith Hospital, London, UK.
- Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
ORCID-Profile: Anna Kyriakidou, Kanyada Koysombat, Alexander N Comninos, Waljit S Dhillo, Ali Abbara
Förderung
- National Institute for Health and Care Research
- Medical Research Council
Zitieren
APA
Kyriakidou, A., Koysombat, K., Comninos, A. N., Dhillo, W. S., & Abbara, A. (2026). Neuroendocrine drivers of polyendocrine metabolic ovarian syndrome ( PMOS ) and the modifying role of adiposity. Journal of Neuroendocrinology, 38(11). https://doi.org/10.1111/jne.70337
Vancouver
Kyriakidou A, Koysombat K, Comninos AN, Dhillo WS, Abbara A. Neuroendocrine drivers of polyendocrine metabolic ovarian syndrome ( PMOS ) and the modifying role of adiposity. Journal of Neuroendocrinology. 2026;38(11). doi:10.1111/jne.70337
BibTeX
@article{Kyriakidou2026,
author = {Kyriakidou, Anna and Koysombat, Kanyada and Comninos, Alexander N and Dhillo, Waljit S and Abbara, Ali},
title = {Neuroendocrine drivers of polyendocrine metabolic ovarian syndrome ( PMOS ) and the modifying role of adiposity},
journal = {Journal of Neuroendocrinology},
year = {2026},
volume = {38},
number = {11},
doi = {10.1111/jne.70337}
}
EUVIMED